• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Editorial: Highlights of a Year in AIDS


Editorial: Highlights of a Year in AIDS

Dr Laurence is professor of medicine and director of the Laboratory for AIDS Virus Research, New York Presbyterian Hospital–Weill Medical College of Cornell University, New York; senior scientific consultant for programs, amfAR, The Foundation for AIDS Research; and editor in chief of The AIDS Reader.

Here are my choices for key achievements and discoveries in HIV/AIDS, from those which heralded the new year 2006 through the most recent findings in early 2007. Several are updates of reports first mentioned in my editorials over the past year.

Three randomized controlled interventions conducted in Africa among general populations of uncircumcised men found that circumcision afforded a protection rate against acquisition of HIV via penile-vaginal intercourse ranging from 48% to 60% during a mean follow-up of about 18 months.1-3 A retrospective study of Ugandan couples showed that circumcised men were also 30% less likely to transmit HIV to their female partners.3

The results for prevention of female-to-male transmission of HIV are equivalent to protection rates provided by some widely used microbial vaccines. These results argue for directed education and swift implementation. Although concerns have been raised about engendering feelings of invulnerability to HIV infection following this procedure, during the first year following circumcision, men did not engage in more risky sexual behaviors than their uncircumcised counterparts, at least in a Kenyan cohort.4

Resistance to at least isoniazid and rifampin occurs in a median of 1.0% (range, 0% to 14.2%) of the 8.7 million worldwide annual cases of tuberculosis (TB).5 It is a huge issue: a person with untreated TB infects, on average, 10 to 15 people each year,6 and treatment of resistant disease requires large expenditures for second-line drugs and up to 2 years of therapy. Concern has escalated with identification of extensively (or extremely) drug-resistant TB (XDR-TB) among 102 people in KwaZulu-Natal, South Africa.7 All were coinfected with HIV. The first 53 XDR-TB isolates represented 10% of all positive cultures from one rural district, and 52 of the 53 patients died as a result of what was essentially untreatable disease.8 These observations illustrate the need for improved worldwide surveillance for drug-resistant TB. This is particularly important among the HIV-infected in countries with high rates of TB drug resistance, such as China, Russia, and India.

The theme of the XVI International AIDS Conference was "Time to Deliver." In a plenary presentation there, Gita Ramjee9 of South Africa suggested extending the ABCs of HIV prevention-A, abstain; B, be faithful; and C, use condoms-to the real world, where compliance with and acceptability of such programs present formidable challenges. She recommended delivery of C, circumcision; D, diaphragm; E, exposure prophylaxis; F, female-controlled methods, such as microbicides; G, genital tract–factor treatments; and H, herpes simplex virus type 2 prevention and treatment, while awaiting development of vaccines for I, immunity.

This is great, although many of the biomedical prevention methods she lists are not yet ready for dissemination. For example, tenofovir was evaluated as preexposure prophylaxis (PrEP) in 936 HIV-negative women from 3 African countries.10 Two HIV infections were identified in the tenofovir group, versus 6 among placebo recipients. But this was not statistically significant, given a power analysis that failed to anticipate the low incidence of HIV infections in the control group, a salutary occurrence that may, nevertheless, make similar studies prohibitively expensive.

Lack of evidence for efficacy has not stopped many from relying on tenofoviras PrEP, however. In 2005, the CDC reported that 7% of uninfected men who have sex with men had taken an AIDS medication before engaging in risky behavior.11 "Taking a T" (tenofovir) appears to be a growing practice in gay dance clubs.11 The risks for selection and spread of resistant strains are clear.

In this issue of The AIDS Reader, the newest protease inhibitor (PI), darunavir (TMC114), is reviewed. And over the past year, novel drug classes, such as CCR5 coreceptor antagonists and maturation and integrase inhibitors, as well as novel agents in existing classes, such as the NNRTI TMC125 (etravirine), entered into advanced stages of clinical study.12 How the genetic barriers to selection of drug resistance, synergy with other antiretrovirals, and other factors will play out in combination therapies is an area of active research.12 For example, the target in HIV for the fusion inhibitor enfuvirtide, the sole agent in this latest class of FDA-approved antiretrovirals, exhibits high and unanticipated genetic variability, which increases in the presence of resistance mutations to NRTIs, NNRTIs, and PIs.13 In addition, and just as unexpectedly, enfuvirtide markedly increased tipranavir/ritonavir trough drug concentrations.14

One promising new agent is the HIV integrase inhibitor MK-0518. It is a diketo acid with no effect on cytochrome CYP3A4,12 allowing its use in multiple combinations. In a 10-day monotherapy study in treatment-naive persons with HIV RNA levels of less than 5000 copies/mL, at least 50% of patients had HIV RNA levels suppressed to below 400 copies/mL.15 In a dose-escalation study in antiretroviral therapy–naive patients of MK-0518 versus efavirenz, each combined with tenofovir and lamivudine, all groups showed a greater than 2.2 log10 decline in HIV RNA level and similar increases in CD4+ T- cell counts, although the rate of HIV RNA level reduction was greater with MK-0518.16

The benefits of and concerns over simplification strategies for both initial treatment of HIV infection and maintenance of chronically infected persons was a prominent topic. A once-daily regimen of tenofovir, emtricitabine, and efavirenz was compared with twice-daily Combivir (zidovudine/lamivudine) plus once-daily efavirenz in a randomized, open-label multicenter study of antiretroviral therapy-naive patients.17 Achievement and maintenance of HIV RNA levels of less than 400 copies/mL and increases in absolute CD4 counts from baseline over 48 weeks were equivalent. In mid-2006, the FDA approved the first 1-pill-a-day antiretroviral "cocktail," Atripla, which contains emtricitabine (200 mg), tenofovir (300 mg), and efavirenz (600 mg).

Apart from a hoped for improvement in medication adherence, as a PI-sparing regimen lacking stavudine, Atripla may also be less likely to cause lipoatrophy, although the neuropsychological side effects linked to efavirenz could be a deterrent. The "forgiveness factor," or period during which drug levels remain above the inhibitory-dose 50% level,18 should be good, offering the possibility of making up a dose on the day following a missed pill.

Ritonavir-boosted PI monotherapy as maintenance has also been studied. In the majority of participants, virus suppressed by standard combination antiretroviral therapy remains inhibited by lopinavir/ritonavir19 or atazanavir/ritonavir20 alone. However, HIV RNA levels "below the bar"-in the 50 to 400 copies/mL range-are more common with monotherapy maintenance than with continued standard antiretroviral therapy.19 The clinical relevance of these findings remains to be determined.

Antiretroviral therapy saves lives: 2.8 million years of life since 1989 in the United States alone, in fact, based on national surveillance and efficacy data and a state transition probability model.21 The average survival from an AIDS diagnosis is now in excess of 14 years. The estimated median survival (from age 25) after diagnosis of HIV infectionis now in excess of 35 years.22 Even among persons with late-stage HIV disease and suboptimal responses to antiretroviral therapy-CD4+ cell counts of less than 200/µL and HIV RNA levels of greater than 100,000 copies/mL-maintaining antiretroviral therapy reduces the incidence of AIDS-related events.23

However, 25% of infected persons in the United States are unaware of their serostatus,24 and of those who are aware, only 57% are receiving care.25 On this basis, it has been estimated that an additional 740,000 years of life might have been saved in the United States had all patients received appropriate treatment.21

In addition, the proportion of deaths attributable to non-AIDS diseases has increased and is related to hepatic and pulmonary conditions and non-AIDS malignancies, with the CD4 count at death increasing over time.26 Hepatitis C virus (HCV) plays a significant role. A recent study from Philadelphia found that HCV-HIV coinfection is associated with worsening liver disease and higher mortality than HCV or HIV monoinfection.27 Non–AIDS-related causes now account for one fourth of all deaths of persons with AIDS; this argues for a shift in the health care model for the HIV-infected population.28

"The assumption that people are just going to be on therapy for the rest of their lives is not a practical assumption," said Clair Rappoport, a member of the Strategies for Management of Antiretroviral Therapy (SMART) protocol committee,29 one of several CD4-guided strategic treatment interruption (STI) trials released in 2006.

The SMART participants included 5472 predominantly antiretroviral therapy–experienced persons from 318 sites in 33 countries who were randomly assigned to an episodic treatment or a drug conservation (DC) regimen versus a viral suppressive (VS) strategy of continuous therapy (CT).30 In the DC arm, highly active antiretroviral therapy was stopped when CD4+ cell counts were greater than 350/µL, then restarted if CD4+ cell counts fell below 250/µL. There was a relative risk of 1.9 for death and 2.5 for clinical progression or death in the DC group, or 3.7 events per 100 person-years (PY) in DC versus 1.5 events per 100 PY in VS (P < .0001) when the study was prematurely terminated as a result of increased adverse events in the DC group.30

A major criticism was the study design, with selection of a relatively low CD4 count at which to restart therapy. Potential benefits of using a much higher restart number were suggested by the STACCATO (Scheduled TreAtment interruptions Compared to Continuous Therapy Outcome) trial, a randomized trial conducted predominantly in Thailand. Four hundred thirty patients received CT or STI, with the latter maintained as long as the CD4+ cell counts were greater than 350/µL.31 The median duration of randomized treatment was 21.9 months; drug savings via STI were 61.2%, with significant differences in side effects between the 2 arms. Virologic failure was equivalent: it occurred in 9 of 284 STI and 6 of 146 CT patients. CD4 count-guided therapy clearly deserves further investigation.

It began with several presentations at the 12th Conference on Retroviruses and Opportunistic Infections, held in February 2005, attempting to define a unified hypothesis to explain the rapidity and depth of T-cell depletion characteristic of HIV/AIDS.32 The gut took center stage in speculations concerning HIV immune pathology and remained there throughout 2006.

Early studies of the GI tract in simian immunodeficiency virus (SIV)-infected rhesus macaques found a profound but selective depletion of CD4+ T cells in the intestine within days of infection, before any changes in peripheral lymphoid tissues.33 This was attributed to the fact that SIV, like HIV, replicates optimally in activated CCR5+ memory CD4+ T cells, a cell type abundant in the GI tract. There was a loss of 50% of memory CD4+ T cells from all lymphoid compartments by days 10 to 14 and an 80% loss at day 17. A similar phenomenon appears to occur in the human GI tract following acute HIV infection.34

Based on cancer chemotherapy models, CD4+ T-cell reconstitution is limited after such massive depletion.35 In AIDS, chronic immune activation imposes an additional homeostatic strain, further draining the memory CD4+ T-cell pool. These changes have been tracked by Daniel Douek's group as the group divides HIV immune pathogenesis into 2 stages. There is massive, very rapid loss of memory CD4+ T cells in the acute phase, a result of direct infection of T cells, followed by immune activation and activation-induced cell death in the chronic phase.36 Circulating lipopolysaccharide has been found in chronically HIV-infected persons, an indicator of microbial translocation from a mucosally compromised gut.36In nonpathogenic SIV infection of sooty mangabeys, such translocation was not seen.

Given all this damage, can we ever hope to achieve immune reconstitution in AIDS? If highly active antiretroviral therapy partially restores mucosal immunity, this could suppress microbe trafficking as one source of chronic immune activation. In fact, lipopolysaccharide levels do decline after antiretroviral therapy, although they still remain above the levels seen in uninfected persons.36 But despite suppressive treatment with highly active antiretroviral therapy during acute and early infection for 1 to 7 years, 50% to 60% depletion of lamina propria lymphocytes persists.37 This has led to the ominous prediction that "although clinically silent over the short term, the long-term consequences of the persistence of this lesion may emerge as the HIV-1-infected population survives longer as a result of the benefits of HAART."37 More research is needed into the efficacy of antiretroviral therapy in the GI tract, as well as T-cell homing to gut tissue, and the influence of microbial products in maintaining an activated immune state there. For example, interleukin 15 can stimulate production of effector memory cells with gut-homing potential in monkeys.37


References1. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial [published correction appears in PLoS Med. 2006;3:e298]. PLoS Med. 2005;2:e298.
2. Russell S. Male circumcision shows promise as defense against HIV transmission. San Francisco Chronicle. December 14, 2006:A-1.
3. McNeil DG Jr. HIV risk halved by circumcision, US agency finds. New York Times. December 14, 2006:A1.
4. Agot KE, Kiarie JN, Nguyen HQ, et al. Male circumcision in Siaya and Bondo districts, Kenya: prospective cohort study to assess behavioral disinhibition following circumcision. J Acquir Immune Defic Syndr. 2007;44:66-70.
5. Aziz MA, Wright A, Laszlo A, et al; WHO/International Union Against tuberculosis and Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet. 2006;368:2142-2154.
6. South African officials isolate woman with deadly TB strain. VOA News. September 13, 2006.
7. Cohen J. Infectious disease. Extensively drug-resistant TB gets foothold in South Africa. Science. 2006;313:1554.
8. Gandhi NR, Moll A, Pawinski R, et al. High prevalence and mortality from extensively-drug resistant (XDR) TB in TB/HIV coinfected patients in rural South Africa. XVI International AIDS Conference; August 13-18, 2006; Toronto. Abstract THLB0210.
9. Ramjee G, Rizdon R. Current non-vaccine HIV prevention trials and the challenges in conducting large phase III efficacy trials. XVI International AIDS Conference; August 13-18, 2006; Toronto. Abstract THBS0102.
10. Peterson L, Taylor D, Clarke EEK, et al. Safety and preliminary effectiveness of tenofovir disoproxil fumarate (TDF) for prevention of HIV infection in women. XVI International AIDS Conference; August 13-18, 2006; Toronto. Abstract THLB0103.
11. Costello D. AIDS pill as party drug? Some HIV-negative men are using tenofovir instead of condoms, hoping it provides protection: physicians say the practice could lead to more infections. Los Angles Times. December 19, 2005.
12. Wong JK, Lampiris H. Covering all the bases: targeting HIV-1 integrase. J Acquir Immune Defic Sydr. 2006;43:507-508.
13. Si-Mohamed A, Piketty C, Tisserand P, et al. Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T-20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene. J Acquir Immune Defic Syndr. 2007;44:1-5.
14. Gonzalez de Requena D, Calcagno A, Bonora S, et al. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS. 2006;20:1977-1979.
15. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1 infected individuals. J Acquir Immune Defic Syndr. 2006;43:509-515.
16. Markowitz M, Nguyen BY, Gotuzzo F, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naive HIV-1 infected patients. XVI International AIDS Conference; August 13-18, 2006; Toronto. Abstract THLB0214.
17. Gallant JE, DeJesus E, Arribas JR, et al; Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260.
18. Murri R, Marcotullio S, Lupoli P, von Schloesser F. Is "once-daily" regimen a key strategy for improving adherence to antiretroviral regimens? J Acquir Immune Defic Syndr. 2006;42:259-260.
19. Daar ES. Measuring below the bar: what is it telling us? AIDS. 2006;20:2385-2387.
20. Swindells S, DiRienzo AG, Wilkin T, et al; AIDS Clinical Trials Group 5201 Study Team. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006;296:806-814.
21. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11-19.
22. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146:87-95.
23. Gandhi T, Wei W, Amin K, Kazanjian P. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy. Clin Infect Dis. 2006;42:878-884.
24. Glynn M, Rhodes P. Estimated HIV prevalence in the United States at the end of 2003. National HIV Prevention Conference; June 12-15, 2005; Atlanta. Abstract T1-B1101.
25. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305-2315.
26. Palella FJ Jr, Baker RK, Moorman AC, et al; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34.
27. Merriman NA, Porter SB, Brensinger CM, Torian LV. Racial difference in mortality among US veterans with HCV/HIV coinfection. Am J Gastroenterol. 2006;
28. Sackoff JE, Hanna DB, Pfeiffer MR, et al. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397-406.
29. Brown D. NIH warns AIDS patients against stopping therapy: study finds people who forgo continuous treatment more likely to develop other illnesses or die. Washington Post. February 7, 2006:A13.
30. Strategies for Management of Antiretroviral Therapy (SMART) Study Group: El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
31. Anaworanich J, Gayet-Ageron A, Le Braz M, et al; the Staccato Study Group. CD4-guided scheduled treatment interruptions compared to continuous therapy: results of the Staccato trial. 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver. Abstract 102.
32. Laurence J. HIV immune pathogenesis: an update from CROI. AIDS Reader. 2005;15:208, 214.
33. Veazey RS, DeMaria MA, Chalifoux LV et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science. 1998;
34. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200:761-770.
35. Hakim FT, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood. 1997;90:3789-3798.
36. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Med. 2006;12:
37. Mehandru S, Poles MA, Tenner-Racz K, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoSMed. 2006;3:2335-2347.

Related Videos
Infectious disease specialist talks about COVID-19 vaccine development
COVID 19 impact on healthcare provider mental health
Physician mental health expert discusses impact of COVID-19 on health care workers
© 2024 MJH Life Sciences

All rights reserved.